Literature DB >> 19694311

Analysis of PCR-RAPD DNA and antibiotic susceptibility profiles of antrum and corpus isolates of Helicobacter pylori from Malaysian patients.

A Norazah1, Wan Z Rasinah, Z Zaili, A Aminuddin, M Ramelah.   

Abstract

This study was conducted to determine whether there was any genetic heterogeneity among Helicobacter pylori strains isolated from the antrum and corpus of the same individual in a Malaysian population and to determine the presence of heterogeneous susceptibility of the isolates by comparing PCR-RAPD and antibiotic profiles. Forty-four H. pylori isolates cultured from the antrum and corpus of 22 patients were analyzed. Antibiotic susceptibility testing was carried out by minimum inhibitory concentration determination, using E-Test method strips. PCR-RAPD was carried out on all the strains and the profiles generated were analysed for cluster analysis. Twenty-nine different PCR-RAPD profiles were observed in the 44 isolates. Fifteen pairs of the isolates from the same patients had the same PCR-RAPD patterns while in 7 pairs, the profiles were different. The strains were clustered into 2 separate clusters at a low coefficient of similarity, where most of the strains were in cluster 1. The degree of similarity was very low among most of the isolates. Most of the patients (16 of 22) were infected with strains that have the same antibiotic susceptibility profiles. Out of these, only 10 pairs shared the same PCR-RAPD and antibiotic profiles. Five pairs of isolates with similar PCR-RAPD profiles differed in their antibiotic profiles due to metronidazole resistance in one of the sites. A large degree of genetic heterogeneity was observed among H. pylori strains circulating among Malaysian patients. An individual patient can be infected with multiple strains and the strains can be antibiotic resistant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694311

Source DB:  PubMed          Journal:  Malays J Pathol        ISSN: 0126-8635            Impact factor:   0.656


  6 in total

1.  HopE and HopD Porin-Mediated Drug Influx Contributes to Intrinsic Antimicrobial Susceptibility and Inhibits Streptomycin Resistance Acquisition by Natural Transformation in Helicobacter pylori.

Authors:  Yixin Liu; Feng Yang; Su Wang; Wenjing Chi; Li Ding; Tao Liu; Feng Zhu; Danian Ji; Jun Zhou; Yi Fang; Jinghao Zhang; Ping Xiang; Yanmei Zhang; Hu Zhao
Journal:  Microbiol Spectr       Date:  2022-03-02

2.  Genomic variability of Helicobacter pylori isolates of gastric regions from two Colombian populations.

Authors:  Andrés Jenuer Matta; Alvaro Jairo Pazos; Javier Andrés Bustamante-Rengifo; Luis Eduardo Bravo
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

Review 3.  Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.

Authors:  Maria Teresa Mascellino; Barbara Porowska; Massimiliano De Angelis; Alessandra Oliva
Journal:  Drug Des Devel Ther       Date:  2017-07-28       Impact factor: 4.162

4.  The analysis of virulence factors and antibiotic resistance between Helicobacter pylori strains isolated from gastric antrum and body.

Authors:  Ji Won Seo; Jae Yong Park; Tae-Seop Shin; Jae Gyu Kim
Journal:  BMC Gastroenterol       Date:  2019-08-07       Impact factor: 3.067

Review 5.  Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis.

Authors:  Ebrahim Kouhsari; Nourkhoda Sadeghifard; Arezoo Khadiv; Hojjat Sayadi; Taghi Amiriani; Sobhan Ghafourian; Hassan Valadbeigi; Marcela Krutova
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-05-20       Impact factor: 3.944

6.  Clonality Analysis of Helicobacter pylori in Patients Isolated from Several Biopsy Specimens and Gastric Juice in a Japanese Urban Population by Random Amplified Polymorphic DNA Fingerprinting.

Authors:  Nariaki Toita; Shin-Ichi Yokota; Nobuhiro Fujii; Mutsuko Konno
Journal:  Gastroenterol Res Pract       Date:  2013-11-17       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.